Shares of drug company Basilea fell dramatically after the FDA refused to approve ceftobiprole, a treatment for MRSA (Methicillin Resistant Staphyloccus Aureus) and other serious infections. Reviewers were concerned about the credibility of three sites involved in the study, which could delay US authorization up to eighteen months.